CureGene's Evategrel Shows Matching China-US PK/PD Data at AHA 2026
SHANGHAI – November 08, 2026 -- CureGene Pharmaceutical reported that its investigational P2Y12 antagonist Evategrel (CG-0255) produced comparable pharmacokinetics and platelet inhibition in Chinese and US healthy volunteers, clearing a key hurdle for running global trials in parallel. The data were presented as a poster at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, held November 6-9.
Two clinical pharmacology studies test ethnic and food effects on oral Evategrel
One study compared oral Evategrel pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese and US participants. The second examined how food affects exposure to the oral formulation and its antiplatelet effect. Both used the same design, with one run in the United States and one in China.